Dr Christos Kyriakopoulos speaks to ecancer at ASCO 2024 about results from the CHAARTED2 trial which evaluated cabazitaxel with abiraterone versus abiraterone alone randomised trial for extensive disease following docetaxel.

223 patients with metastatic CRPC previously treated with androgen deprivation therapy plus docetaxel for hormone-sensitive prostate cancer were randomised (1:1) to abiraterone/prednisone plus cabazitaxel or abiraterone/prednisone alone. 

Dr Kyriakopoulos reports that a progression-free survival benefit of 5 months was seen with patients who received the added cabazitaxel.